J&J Announces Major Expansion of 340B Contract Pharmacy Limits; Pushback Is Likely

Johnson & Johnson signage in front of building
Johnson & Johnson is poised to become the first drug maker to place a condition on 340B sales and deliveries to covered entity in-house pharmacies.

Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.

On March 7, it is poised to become the first drug maker to place a

Read More »

GSK Announces Refunds for 340B Overcharges on Respiratory Drugs

GSK GlaxoSmithKline logo on office building
GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in Q1 2021.

Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.

The refund notice posted Feb. 2 on the U.S. Health

Read More »

Bayer: 340B “Is Enriching Middlemen Versus Benefitting Patients”

Bayer wordmark on building
Bayer added a previously excluded drug to its list of products that face contract pharmacy restrictions.

While the 340B program “has merit when used as intended,” it has “strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.

Bayer gave the statement

Read More »

Breaking News

EMD Serono Is the Second Drug Maker Today to Impose Conditions on 340B Contract Pharmacy, and the 21st Overall

EMD Serono wordmark on building
Beginning Oct. 1, EMD Serono will extend its contract pharmacy restrictions to all 340B covered entities.

EMD Serono today became the 21st pharmaceutical manufacturer to impose conditions on 340B pricing involving drug shipments to contract pharmacies.

Bayer announced conditions on 340B sales involving contract pharmacies earlier today. The companies’ announcements came two days after

Read More »

Breaking News

Bayer Is the 20th Drug Maker to Impose Conditions on 340B Contract Pharmacy

Bayer wordmark on side of building
Bayer will no longer exempt federal grantees from its 340B contract pharmacy policy as of Oct. 1.

Bayer Healthcare Pharmaceuticals starting March 1 is imposing limits on hospitals’ replenishment orders of 340B-priced drugs shipped to contract pharmacies. It said it is voluntarily letting 340B grantee covered entities continue to use multiple contract pharmacies to dispense 340B drugs.

Read More »

Astellas Notifies 340B Entities About Antifungal’s Updated NDC

Astellas wordmark on building
Astellas says the old and new NDCs for its antifungal drug Cresemba are interchangeable in compliant 340B inventory replenishment models.

Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company

Read More »

340B “Overdue for Reform,” Industry Trade Group BIO Says in Blog

Screenshot of bionews.com 340B drug discount program story
The 340B program “is buckling under its own weight and overdue for reform,” BIO says in its blog.

The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.

BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent

Read More »

Janssen Providing Refunds for 340B Overcharges During Q1 2020

Janssen building signage
Janssen Pharmaceuticals is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.

Johnson & Johnson’s Janssen Pharmaceuticals division is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.

The U.S. Health Resources and Services Administration (HRSA) posted J&J’s refund notice yesterday. The company said the 340B

Read More »

Lilly Says 340B Entities Can’t Designate Central Fill Pharmacies as Contract Pharmacies

Lilly wordmark on top of building
Pharmaceutical giant Eli Lilly has significantly escalated its restrictions on access to 340B pricing in the contract pharmacy setting, the company announced June 19 on the drug industry vendor site 340B ESP.

Drug manufacturer Eli Lilly late last month again updated its conditions on 340B pricing when covered entities use contract pharmacies.

Lilly was the first company to impose such conditions, starting with one drug in July 2020 then expanding to

Read More »

Alcon Providing Refunds for 340B Overcharges on 22 Products

Alcon wordmark on a building
Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.

Swiss eye care drug manufacturer Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.

The U.S. Health Resources and Services Administration posted Alcon’s public notice about

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live